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 Essential thrombocythemia (ET) has a risk of malignant transformation 
 We determined transformation to acute myelogenous leukemia (AML)  
 Standardized incidence ratio of AML was high in ET patients on 
hydroxycarbamide  
 No cases of AML occurred in ET patients treated with anagrelide 
 Rates for non-AML cancers were similar in the two groups 
 
 
Abstract 
EXELS, a post-marketing observational study, is the largest prospective study of 
high-risk essential thrombocythemia (ET) patients, with an observation time of 5 
years. EXELS found higher event rates of acute leukemia transformation in patients 
treated with hydroxycarbamide (HC). In the current analysis, we report age-adjusted 
rates of malignant transformation from 3460 EXELS patients exposed to HC, 
anagrelide (ANA), or both. At registration, 481 patients had ANA treatment without 
HC exposure, 2305 had HC without ANA exposure, and 674 had been exposed to 
both. Standard incidence ratios (SIRs) were calculated using data from the Cancer 
Incidence in Five Continents database to account for differences in age-, gender-, 
and country-specific background rates. SIRs for acute myelogenous leukemia (AML) 
were high in ET patients. SIRs for AML were high in HC-treated patients, but AML 
was rare in ANA-treated patients; no cases of AML were found in patients only 
treated with ANA. No statistically significant difference was seen between SIRs for 
ANA and HC treatment for AML or skin cancer. SIRs for other cancers were similar in 
the HC and ANA groups and close to 1, indicating little difference in risk. Although 
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statistically inconclusive, this study strengthens concerns regarding possible 
leukemogenic risk with HC treatment. (NCT00202644) 
 
Key words: acute myelogenous leukemia, malignant transformation, anagrelide, 
hydroxycarbamide 
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1. Introduction 
Essential thrombocythemia (ET) is the most “benign” of the myeloproliferative 
neoplasms (MPNs), with a near-normal expected life span [1,2]. The median age at 
diagnosis is approximately 60 years, but a substantial proportion of patients with ET 
are younger than 60 years at diagnosis. Furthermore, the life expectancy in the 
general population has progressively improved and reached a point where individuals 
aged 65 years have an average life expectancy of around 20 years in developed 
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countries. Therefore risks or side effects associated with ET treatments are 
especially pertinent. 
The main goal of treatment in ET is to prevent thrombosis and bleeding, which 
represent the most common complications of ET. Risk stratification traditionally 
includes age > 60 years, previous thrombohemorrhagic events, and platelet counts 
> 1500x109/L. Patients having any of these risk factors are considered high risk, and 
all others are considered low risk [3]. 
First-line cytoreductive therapy in ET in most countries is hydroxycarbamide 
(HC), especially in older patients [4]. Anagrelide (ANA; Xagrid®), a selective platelet-
reducing agent is an alternative therapy, registered as a second-line therapy for ET in 
Europe; however, ANA is often used as first-line therapy in younger patients due to 
the concern for a possible leukemogenic risk connected to HC [4]. In the United 
States, ANA is registered for treatment of thrombocythemia in MPNs, and in some 
countries, (i.e., Austria, Japan) as first-line therapy for ET. 
The Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study is the 
largest prospective study ever performed in patients with high-risk ET; it has a 
follow-up of 5 years from registration, and information on treatment received from 
diagnosis [5]. More than 90% of the patients were treated with either ANA or HC; 
hence, the study offers a unique and important opportunity to investigate the effect of 
these drugs on the event rate of acute leukemia and myelodysplastic syndrome 
(MDS), as well as on the development of non-hematological malignancies. The 
thrombohemorrhagic complications and risk factors have been previously published 
[5]. This study identifies concerns regarding the risk for acute leukemia and second 
malignancies as a function of treatment. 
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2. Subjects and methods 
 
2.1 Patients 
 
The EXELS study was a prospective, 5-year, observational study recruiting 
3649 high-risk ET patients from 125 centers in 13 European countries between 2005 
and 2009, with an observation time of 5 years (NCT00202644). The main objectives 
of the study were safety and pregnancy [5]. 
The EXELS study was initiated in 2005 and finished in June 2014. All centers 
obtained local ethical approval prior to patient enrollment. Patients were eligible for 
study enrollment if they had a known date of birth; confirmed diagnosis of ET; and the 
presence of 1 or more high-risk features at the date of screening, according to the 
treating physician: age > 60 years, a history of thrombohemorrhagic events, or initial 
platelet count > 1000x109/L (the accepted platelet high-risk criterion when the study 
was initiated). At the time of study initiation, either Polycythemia Vera Study Group 
(PVSG) (10) or World Health Organization (WHO) 2001 or 2008 (11) diagnostic 
criteria may have been used; no particular one was mandated. When the study was 
initiated in 2005, no recurrent mutations had been identified in ET, thus such data 
were not prospectively collected. For inclusion in the study, patients were required to 
be either already prescribed cytoreductive therapy or in need of treatment at the time 
of study registration. Treatment was given at the discretion of the investigators. The 
majority (95%) of patients had previous treatment; 5% were treatment-naïve at 
registration. Previous cytoreductive treatment was recorded at registration, and 
changes in treatment were recorded during follow-up. Data were collected using an 
electronic data capture system at registration, every 6 months, and upon pre-defined 
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events such as thrombohemorrhagic events, transformation, non-hematologic 
malignancies, serious adverse events, or death. Two patients were excluded from the 
study because of an unknown date of birth. Thus, 3647 participants from the EXELS 
study were included in the cohort investigated in this study. Baseline study enrollment 
characteristics are shown in Table 1. Results on thrombosis, hemorrhage, and safety 
have been published previously [5]. Written informed consent was obtained from all 
participants in accordance with the Declaration of Helsinki. 
 
2.2 Statistical analysis 
 
 Exposure to ANA and HC was recorded at study enrollment, based on 
recorded patient history. Only patients ever treated with HC or ANA alone or in 
combination were included in the current analysis. Transitions between different 
treatment groups were allowed during follow-up. All patients were followed until death 
or until end of study. The duration of exposure was calculated from the treatment 
history before enrollment and observation during study follow-up. Relative risks were 
only estimated for events occurring within the observed study period, from the 
registration date to the end of follow-up. One hundred eleven patients switched from 
ANA to HC, and 291 patients switched from HC to ANA during the study. For a 
patient to be categorized in one of the treatment groups, we required a minimum 
exposure time of at least 180 days. The overall risk for hematological transformation 
or non-hematological malignancy after study enrollment was studied by estimating 
the cumulative incidence, treating death from other causes as a competing risk. To 
compare treatments with regard to transformations and non-hematologic 
malignancies, we used standardized incidence ratios (SIRs) standardized on age, 
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gender, and country of residence. Background incidence rates were retrieved from 
the Cancer Incidence in Five Continents (CI5) database [http://ci5.iarc.fr]. Age during 
follow-up was split into 5-year categories (15–19, 20–24, etc.). Byar’s Poisson 
approximation was used to estimate 95% confidence intervals (CIs). In the case of no 
events, the SIR was zero and CIs were calculated accordingly. Relative risks for HC 
versus ANA were calculated as ratios of SIRs [6]. Bias-corrected accelerated 
bootstrap with 10000 samples was used to estimate 95% CIs around these risk ratios 
[7]. All data management was done with SAS version 9.4 (SAS Institute, Cary, NC, 
USA), and all statistical analysis was performed in R version 3.2.1. (R Foundation for 
Statistical Computing, Vienna, Austria). Country incidence rates for MDS could not be 
found in the CI5 database, and therefore, MDS was not included in this analysis. 
 A sensitivity analysis was performed on the subset of patients with 
information on the date of ET diagnosis. Further sensitivity analyses included only 
incident cases (ET diagnosis within 1 year of registration). Analyses were stratified by 
time between ET diagnosis and registration. To investigate early and late risks, 
follow-up time was split into different durations of exposure. 
 
3. Results 
 
A total of 3460 patients were exposed to HC, ANA, or both at registration. 
Disease duration was long. Thirteen per cent of the patients were diagnosed with ET 
>10 years before registration, and only 23 % received their ET diagnosis within a 
year before registration. Patients were categorized according to treatment exposure 
at registration as follows: 481 patients had ANA treatment at registration and had not 
been exposed to HC, 2305 had HC and had not been exposed to ANA, and 674 
AC
CE
PT
ED
 M
AN
US
CR
IPT
9 
 
patients were exposed to both drugs (Fig. 1). Five hundred forty patients switched 
from HC to ANA, and 116 switched from ANA to HC before registration. The 
medication distribution by age group was as follows: < 40 years (n = 249): ANA 41%, 
HC 21%, ANA+HC 24%; 40–59.9 years (n = 931): ANA 26%, HC 41%, ANA+HC 
26%; 60–79.9 years (n = 1994): ANA 6%, HC 75%, ANA+HC 15%; 80+ years  
(n = 473): ANA 3%, HC 81%, ANA+HC 11%. Median age was 51 years in the ANA 
group and 71 years in the HC group. 
 
3.1 Non-hematologic malignancies 
 
One hundred seventy-four cases of non-hematologic cancer, including 35 
cases of skin cancer, were recorded (Table 2). The SIRs for all malignancies were 
close to 1 for all treatment groups (Table 3), indicating similar risks as in the 
background population. For all skin cancers, including melanoma, the SIR for 
patients who received HC treatment was higher than expected and higher than for 
patients who received ANA (1.15 versus 0.45, respectively). When melanoma was 
excluded, the figures changed only marginally (Table 3). However, possibly due to 
the low number of events, the CIs were wide, and no statistically significant difference 
was found between treatments (Table 3). 
 
3.2 Acute leukemia/ myelodysplastic syndrome 
 
All observed cases of acute leukemia were myelogenous (AML). AML 
emerged at approximately the same rate during the 5 years of observation.  
Sixty-seven cases of AML and 19 cases of MDS were recorded (Table 2). The 
SIRs for AML were markedly elevated for all treatment groups except ANA, indicating 
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a much higher risk for AML in patients with ET compared with the background 
population (Table 3). Overall, 39 of 67 AML cases were found in the HC group (8970 
person-years of treatment, SIR 39.7). Baseline characteristics of these patients are 
presented in Supplemental Table 1. Another 20 AML patients were found in the 
group that switched from HC to ANA (2934 person-years of treatment, SIR 91.5), 
Table 3. No cases of AML were found in the ANA-only group (1905 person-years of 
treatment, SIR 0), and only 3 cases were found in the group switching from ANA to 
HC during the study (Table 3). As the number of AML cases in the ANA-only group 
was 0, no statistical expression can be calculated for the difference to the HC group. 
For patients who changed therapy, the risk ratio for developing AML for 
patients who switched from HC was more than doubled (2.30–2.52), irrespective of 
minimal exposure time (Table 4). A calculation of risk ratio for patients who switched 
from ANA to HC, based on the only 3 AML cases in this group, is more uncertain, but 
also showed an increased risk ratio (1.72–1.70; Table 4). As mentioned previously, 
there are no background data for MDS in the CI5 database. In a separate analysis, 
the MDS cases were added to the AML cases, using the AML background SIR, but 
this did not change the results (data not shown). Two patients in the HC group who 
developed AML had previous treatment with busulphan, 4 with pipobroman.  
The rate of AML occurrence did not change over the time of the study, nor was 
there an increased rate of leukemia with increasing time from diagnosis. 
 
4. Discussion 
These data from the EXELS study offer an opportunity to compare malignant 
transformation for the 2 main treatments used in high-risk ET. Higher event rates for 
non-hematologic malignancies were previously shown in this cohort. We have also 
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previously shown that the event rate for AML per 100 years of exposure in the 
EXELS study was lower in the ANA group compared with other cytoreductive 
treatment (0.07 versus 0.28 per 100 years exposure, respectively) and transformation 
to MDS only occurred in the HC group (event rate 0.12 per 100 years exposure) [5]. 
However, these data are difficult to interpret with certainty due to the difference 
between the age of patients receiving HC and ANA and the known influence of age 
on the incidence of malignancies. Because treatment was given at the discretion of 
the treating physician, there is a possible bias if HC was given in cases that the 
physicians considered more aggressive. The influence of the age difference between 
the ANA and HC group in the present analysis was handled by the use of SIRs. 
Importantly, the difference between the treatment groups persisted in the SIR 
analysis. 
We found that not only did patients with ET in the EXELS study have a 
substantially increased risk for AML development, but there was also a highly skewed 
distribution of AML cases between the HC and ANA treatment groups. Interestingly, 
no patient in the ANA-only group developed AML during 1905 person-years of ANA 
treatment (SIR 0.0), whereas 39 patients in the HC group did so during the 8970 
person-years of HC treatment. Compared with the background population, the SIR 
for AML was 40-fold higher than expected under HC exposure. The SIR for patients 
who switched from HC to ANA was even higher, approximately 90-fold, with an 
observed number of 20 versus an expected of 0.22 during 2934 person-years. The 
fact that two of the AML patients in the HC group had previous treatment with 
busulphan and four with pipobroman, gives support to previous reports on leukaemia 
risk with combination of HC and other chremotherapy.  
AC
CE
PT
ED
 M
AN
US
CR
IPT
12 
 
 Acute leukemia is a complication of ET and occurs even in the absence of 
treatment [8], making it difficult to conclude whether or not a certain drug is 
leukemogenic. Two previous studies comparing HC and ANA treatment, the 
ANAHYDRET study [9] and the PT1 study [10], have reported leukemia rates. In the 
ANAHYDRET study no cases of leukemia transformation were found; in the PT1 
study there were 10, 6 vs 4 for HC and ANA, respectively, but no further statistical 
analysis was made. It is generally accepted that busulfan, P32, pipobroman, and a 
combination of any cytostatic drugs increase the risk for leukemia transformation [11]. 
With regard to HC, the standard first-line therapy for ET in most countries, the 
published data are conflicting [11,12], and there is no consensus about how to 
interpret the evidence [13–15]. However, concern about potential leukemogenicity of 
HC therapy influences treatment choice, as well as published guidelines. “Caution” 
with HC in younger patients is advocated in the European LeukemiaNet (ELN) 
recommendations [3]. HC is second-line therapy in younger patients in guidelines in 
many countries, and studies on treatment choice in Europe show that a minority of 
patients aged < 40 years receive HC treatment. Instead, ANA is mostly used as first-
line therapy in younger patients, also previously demonstrated from the EXELS data 
[4]. Notably, the high SIR for AML in patients who switched from HC to ANA may be 
interpreted as a higher risk for patients resistant to HC, in line with the findings of 
Alvarez-Larran et al. in patients with polycythemia vera [16]. Alternatively, it could be 
interpreted as a higher risk for patients exposed to both drugs, which seems less 
likely, because ANA has no mutagenic properties, and we observed no cases of AML 
in patients exclusively treated with ANA. 
Patients with ET have a long expected survival. Even when diagnosis is made 
at around 65 years of age, high-risk patients will get cytoreductive therapy for 
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decades. These facts make the risk–benefit balance of treatment particularly 
sensitive. Therefore, minimizing the risk of treatment damage is one of the central 
goals of management [3], especially vis-à-vis life-threatening complications like 
transformation to acute leukemia. This is the reason why cytostatic drugs with known 
or suspected leukemogenicity are avoided in younger patients (sometimes defined as 
< 40 years of age, sometimes < 60 years) with a long expected treatment duration. In 
our view, the data we present here strengthen concerns regarding a possible 
leukemogenic effect of HC. The lack of statistically significant differences between 
HC- and ANA-treated patients and the development of AML may either be due to a 
true lack of difference or that this very large study lacks the power to demonstrate a 
difference. 
The rate of AML occurrence did not change over time. This may, however, be 
an artefact, as the patients were included in this study at varying times from 
diagnosis, but the complication of acute leukemia was studied only after registration. 
This means that patients with ET who had developed AML after diagnosis and before 
the start of the study could not be included in the study. This, in turn, infers a risk for 
“immortal time bias”: the patients included may be long-term survivors compared with 
other patients with ET, and patients prone to develop AML early may be under-
represented in the study. 
For skin cancer, the SIR for HC-treated patients was slightly higher than in a 
normal population and higher than in the ANA group. In spite of these trends, there 
was no statistically significant difference between HC and ANA groups. Nonetheless 
we continue to recommend scrutiny for the development of skin cancer in patients 
with receiving treatment. 
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A wide range of other cancers were recorded, with no other group being as 
large as skin cancer. For these malignancies the SIRs were close to 1, indicating no 
increased risk for any treatment group. This is another important finding because the 
prevalence of cancer survivors is high and concerns that ET treatments might 
influence either the development or relapse of such cancers could impact treatment 
decisions. However, other smaller studies have shown conflicting results [17,18]. 
The current study adds to the evidence that the risk for AML is strongly 
increased in patients with ET compared with a normal population. In EXELS, there 
was also a consistent numerical difference in the incidence of AML between patients 
receiving HC versus ANA treatment, even if the difference did not reach statistical 
significance. The study thus strengthens concern for a possible leukemogenic effect 
of HC, and the caution advocated by the ELN consensus treatment 
recommendations [3] seems well advised. 
Furthermore, patients switching therapy, particularly from HC to ANA, had a 
significantly increased SIR for AML compared with those who received HC, 
suggesting that patients needing to switch therapy are at increased risk. Skin cancer 
was also more common in HC-treated patients and showed an SIR slightly higher 
than a normal population, but was not statistically significantly different from ANA-
treated patients. Even during a substantial person-year experience and a follow-up of 
5 years, no new concerns emerged related to ET or to either drug regarding other 
non-hematological malignancies. 
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Fig. 1. Distribution of Patients Exposed to ANA and HC in the EXELS Study. 
Two patients of those initially registered were excluded because of unknown date of 
birth. *Dates were missing In 18 patients exposed to both drugs. 
FIGURE FILE UPLOADED SEPARATELY  
Abbreviations: ANA = anagrelide, HC = hydroxycarbamide 
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Table 1 
Baseline characteristics of the cohort of patients with essential thrombocythemia at 
registration. 
 
  
Total  
(N = 
3649) 
None 
(N = 187) 
HC 
(N = 2305) 
ANA 
(N = 481) 
HC → 
ANA 
(N = 540) 
ANA → 
HC 
(N = 116) 
Gender: female, n (%) 2238 (61) 126 (67) 1399 (61) 296 (62) 336 (62) 74 (64) 
Age in years at 
registration, n (%)                         
  <40 249 (7) 34 (18) 51 (2) 102 (21) 44 (8) 15 (13) 
  40–59 931 (26) 59 (32) 382 (17) 240 (50) 192 (36) 52 (45) 
  60–79 1994 (55) 77 (41) 1487 (65) 124 (26) 253 (47) 46 (40) 
  80+ 473 (13) 17 (9) 385 (17) 15 (3) 51 (9) 3 (3) 
Treatment exposure at 
registration, n (%)                         
  None 187 (5) 187 (100) 0 (0) 0 (0) 0 (0) 0 (0) 
  HC 2305 (63) 0 (0) 2305 (100) 0 (0) 0 (0) 0 (0) 
  ANA 481 (13) 0 (0) 0 (0) 481 (100) 0 (0) 0 (0) 
  HC and then ANA 540 (15) 0 (0) 0 (0) 0 (0) 540 (100) 0 (0) 
  ANA and then HC 116 (3) 0 (0) 0 (0) 0 (0) 0 (0) 116 (100) 
  Had received both 
drugs, dates missinga 18 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Years between ET 
diagnosisb and 
registration, n (%)                         
  <1 744 (23) 14 (9) 571 (28) 108 (26) 38 (9) 8 (8) 
  1–2 406 (13) 20 (12) 285 (14) 47 (11) 43 (10) 9 (9) 
  3–4 882 (27) 51 (31) 548 (27) 123 (29) 116 (26) 37 (36) 
  5–9 767 (24) 54 (33) 432 (21) 102 (24) 140 (31) 39 (38) 
  10+ 413 (13) 25 (15) 229 (11) 41 (10) 108 (24) 9 (9) 
 
Abbreviations: ANA = anagrelide, ET = essential thrombocythemia, HC = 
hydroxycarbamide. 
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a Treatment exposure at registration could not be assessed for n = 18 subjects since 
date of first treatment with hydroxycarbamide/anagrelide was not available. 
b Date of diagnosis could not be ascertained for n = 435 subjects. 
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Table 2 
Total number of observed events in the study.  
 
 
Acute myeloid leukemia 67 
Myelodysplastic syndromea 19 
Skin cancer, including six malignant 
melanoma 
35 
Digestive organs 29 
Respiratory organs 28 
Male genital organs  21  
Breast 18 
Mesothelial and soft tissues 10 
Urinary tract 10 
Female genital organs 6 
Eye, brain and central nervous system 5 
Thyroid and other endocrine glands 5 
Other sites 7 
Chronic myeloid leukaemia 1 
Patients with more than one cancer 
diagnosed 
22 
Total number of cancer diagnoses 261 
 
a 3 patients had myelodysplastic syndrome first and then acute myeloid leukemia 
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Table 3 
Standardized incidence ratios with 95% confidence intervals. A minimum of 180 days 
on drug required to be classified as exposed. 
 
 Observed Expected 
Person-
years SIR 95% CI 
Acute myeloid leukemia (C92.0)a      
ET without HC/ANA 0 0.03 331 0.00 (0.00–139) 
ET with HC 39 0.98 8970 39.7 (28.3–54.3) 
ET with ANA 0 0.08 1905 0.00 (0.00–45.7) 
ET with HC and then ANA 20 0.22 2934 91.5 (55.9–141) 
ET with ANA and then HC 3 0.04 802 68.5 (13.8–200) 
Skin cancer (C43-C44)      
ET without HC/ANA 0 0.66 331 0.00 (0.00–5.64) 
ET with HC 28 24.3 8967 1.15 (0.77–1.67) 
ET with ANA 1 2.21 1905 0.45 (0.01–2.52) 
ET with HC and then ANA 5 5.38 2941 0.93 (0.30–2.17) 
ET with ANA and then HC 1 1.05 802 0.95 (0.01–5.30) 
Skin cancer, other (C44)      
ET without HC/ANA 0 0.56 331 0.00 (0.00–6.61) 
ET with HC 24 21.2 8968 1.13 (0.72–1.68) 
ET with ANA 1 1.76 1905 0.57 (0.01–3.16) 
ET with HC and then ANA 4 4.51 2941 0.89 (0.24–2.27) 
ET with ANA and then HC 0 0.83 802 0.00 (0.00–4.47) 
All cancers (C00-C96)      
ET without HC/ANA 0 4.64 331 0.00 (0.00–0.80) 
ET with HC 159 166 8937 0.96 (0.81–1.12) 
ET with ANA 8 15.4 1899 0.52 (0.22–1.02) 
ET with HC and then ANA 53 39.1 2906 1.36 (1.02–1.77) 
ET with ANA and then HC 7 8.31 795 0.84 (0.34–1.74) 
 
Abbreviations: ANA = anagrelide, CI = confidence interval, ET = essential 
thrombocythemia, HC = hydroxycarbamide, SIR = standardized incidence ratio. 
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a Five patients with acute myeloid leukaemia with exposure to both HC and ANA were 
not included in the analysis, because there is uncertainty about which drug was given 
first. 
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Table 4 
Risk ratios of standardized incidence ratios with bootstrapped 95% confidence 
intervals for the risk of acute myeloid leukaemia in patients changing exposure.  
 
  HC→ANA versus HC ANA→HC versus HC 
Minimal exposure time Risk ratio 95% CI Risk ratio 95% CI 
  180 days 2.30 (1.39–3.32) 1.72 (0.72–3.01) 
  One day 2.52 (1.59–3.63) 1.70 (0.72–3.02) 
 
Abbreviations: ANA = anagrelide, CI = confidence interval, HC = hydroxycarbamide  
Patients switching from HC to ANA and vice versa were assessed. The reference 
group was patients on HC only. Two analyses are shown: one with the restriction of 
180 days on a drug is required to be classified as exposed, one without this 
restriction. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
